First Trust Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$155M Buy
168,601
+1,305
+0.8% +$1.32M 0.11% 223
2025
Q4
$180M Buy
167,296
+90,845
+119% +$86.9M 0.13% 190
2025
Q3
$58.3M Sell
76,451
-59,620
-44% -$44.4M 0.04% 509
2025
Q2
$106M Buy
136,071
+21,050
+18% +$16.4M 0.09% 285
2025
Q1
$95M Buy
115,021
+10,479
+10% +$8.72M 0.08% 290
2024
Q4
$80.7M Buy
104,542
+15,820
+18% +$13.1M 0.07% 348
2024
Q3
$78.6M Buy
88,722
+1,349
+2% +$1.21M 0.07% 306
2024
Q2
$79.1M Buy
87,373
+5,657
+7% +$4.53M 0.08% 267
2024
Q1
$63.6M Sell
81,716
-5,159
-6% -$3.67M 0.06% 391
2023
Q4
$50.6M Sell
86,875
-366,393
-81% -$214M 0.06% 431
2023
Q3
$243M Sell
453,268
-24,058
-5% -$12.4M 0.29% 75
2023
Q2
$224M Sell
477,326
-112,331
-19% -$47.1M 0.25% 95
2023
Q1
$202M Sell
589,657
-69,962
-11% -$23.6M 0.23% 109
2022
Q4
$241M Sell
659,619
-69,389
-10% -$24.6M 0.29% 66
2022
Q3
$236M Buy
729,008
+507,733
+229% +$161M 0.31% 66
2022
Q2
$71.7M Sell
221,275
-145,386
-40% -$43.6M 0.09% 331
2022
Q1
$105M Sell
366,661
-1,006
-0.3% -$259K 0.11% 238
2021
Q4
$102M Sell
367,667
-53,007
-13% -$13.4M 0.1% 246
2021
Q3
$97.2M Buy
420,674
+31,890
+8% +$7.87M 0.1% 245
2021
Q2
$89.1M Buy
388,784
+7,632
+2% +$1.53M 0.1% 273
2021
Q1
$71.2M Sell
381,152
-1,313,161
-78% -$257M 0.09% 318
2020
Q4
$286M Buy
1,694,313
+128,613
+8% +$19.2M 0.38% 45
2020
Q3
$232M Buy
1,565,700
+458,790
+41% +$71M 0.37% 45
2020
Q2
$182M Buy
1,106,910
+227,392
+26% +$34.9M 0.32% 55
2020
Q1
$122M Sell
879,518
-138,151
-14% -$19M 0.28% 63
2019
Q4
$134M Buy
1,017,669
+82,786
+9% +$9.6M 0.23% 82
2019
Q3
$105M Sell
934,883
-40,467
-4% -$4.51M 0.2% 105
2019
Q2
$108M Buy
975,350
+226,281
+30% +$26.6M 0.2% 109
2019
Q1
$97.2M Sell
749,069
-173,344
-19% -$21.1M 0.19% 122
2018
Q4
$107M Buy
922,413
+542,013
+142% +$60.5M 0.25% 68
2018
Q3
$40.8M Buy
380,400
+98,646
+35% +$9.86M 0.08% 303
2018
Q2
$24M Sell
281,754
-256,036
-48% -$21M 0.05% 483
2018
Q1
$41.6M Buy
537,790
+60,500
+13% +$4.87M 0.1% 242
2017
Q4
$40.3M Buy
477,290
+95,584
+25% +$8.13M 0.1% 258
2017
Q3
$32.7M Sell
381,706
-15,024
-4% -$1.23M 0.08% 283
2017
Q2
$32.7M Buy
396,730
+167,537
+73% +$13.7M 0.09% 277
2017
Q1
$19.3M Sell
229,193
-60,182
-21% -$4.82M 0.05% 502
2016
Q4
$21.3M Sell
289,375
-31,695
-10% -$2.36M 0.06% 431
2016
Q3
$25.8M Buy
321,070
+171,626
+115% +$13.7M 0.08% 341
2016
Q2
$11.8M Buy
149,444
+34,615
+30% +$2.61M 0.04% 635
2016
Q1
$8.27M Sell
114,829
-566,503
-83% -$42.9M 0.03% 742
2015
Q4
$57.4M Buy
681,332
+90,594
+15% +$7.52M 0.15% 143
2015
Q3
$49.4M Buy
590,738
+489,742
+485% +$41.3M 0.14% 149
2015
Q2
$8.43M Sell
100,996
-390,225
-79% -$29.7M 0.02% 837
2015
Q1
$35.7M Sell
491,221
-245,440
-33% -$17.5M 0.1% 218
2014
Q4
$50.8M Sell
736,661
-449,168
-38% -$30.3M 0.17% 131
2014
Q3
$76.9M Sell
1,185,829
-65,664
-5% -$4.16M 0.3% 49
2014
Q2
$77.8M Sell
1,251,493
-321,066
-20% -$19.2M 0.32% 34
2014
Q1
$92.6M Buy
1,572,559
+483,609
+44% +$27M 0.41% 21
2013
Q4
$55.5M Buy
1,088,950
+161,502
+17% +$8.09M 0.27% 48
2013
Q3
$46.7M Buy
927,448
+158,895
+21% +$8.32M 0.25% 65
2013
Q2
$37.8M Buy
+768,553
New +$41.8M 0.25% 70

Other funds holding LLY

First Trust Advisors's LLY Position: Q1 2026 in Review

First Trust Advisors increased its Eli Lilly (LLY) stake by 0.78% in Q1 2026, buying an estimated $1.32M and bringing the position to 168,601 shares worth $155M. The position accounts for 0.11% of the portfolio, ranked #223.

First Trust Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $286M in Q4 2020. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • First Trust Advisors held 168,601 shares of Eli Lilly worth $155M as of Q1 2026.
  • First Trust Advisors bought 1,305 Eli Lilly shares in Q1 2026, an estimated $1.32M.
  • Eli Lilly made up 0.11% of First Trust Advisors's portfolio in Q1 2026, its #223 holding.
  • First Trust Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • First Trust Advisors's Eli Lilly position peaked at $286M in Q4 2020.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.